Picture loading failed.

Pre-Made Apitegromab biosimilar, Whole Mab: Anti-pro-GDF-8 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Apitegromab (SRK 015) is an anti-promyostatin monoclonal antibody that is being developed by Scholar Rock, for the treatment of spinal muscular atrophy (SMA), muscle-wasting disorders and spinal cord injuries.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-030-1mg 1mg 3090
GMP-Bios-ab-030-10mg 10mg Inquiry
GMP-Bios-ab-030-100mg 100mg Inquiry
GMP-Bios-ab-030-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Apitegromab biosimilar, Whole Mab: Anti-pro-GDF-8 therapeutic antibody
INN Name Apitegromab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure6umx:HL:hl
Year Proposed2020
Year Recommended2021
CompaniesScholar Rock
Conditions Approvedna
Conditions ActiveSpinal muscular atrophy;Muscular atrophy;Spinal cord injuries
Conditions Discontinuedna
Development Techna